Serum Amyloid A (SAA) in Stable COPD Patients Is Associated with the Frequent Exacerbator Phenotype - ATS 2020

Serum Amyloid A (SAA) in Stable COPD Patients Is Associated with the Frequent Exacerbator Phenotype

09. COPD, Emphysema, Chronic Bronchitis, Alpha-1 Antitrypsin Deficiency -> Adult -> Physiology/Pathophysiology

Serum Amyloid A (SAA) in Stable COPD Patients Is Associated with the Frequent Exacerbator Phenotype

Poster Board Number

815

Presenter:

D. Zhao

Session Number

B24

Session Title:

B24 - BIOMARKERS IN COPD

Session Type:

Poster Discussion Session

Authors

D. Zhao
H. Rossiter
A. Abbasi
W. Zhong
Q. Yang
X. Guo
Y. Zhou
T. Li
R. Casaburi
N. Zhang

Audio Upload

Previous Eposter

Biomarker-Based Clustering of Patients with COPD and the Association with Lung Function, Dyspnea and Health Status

Next Eposters

Reduced Pneumococcal Antibody Function Is Associated with Exacerbations of COPD in SPIROMICS

Evaluating Current Discharge Practices After Acute COPD Exacerbation for Areas of Improvement to Ensure Delivery of Quality Care

Burden of Respiratory Symptoms in Older Adults with Underdiagnosed and Misdiagnosed of COPD: Results from the Canadian Longitudinal Study of Aging

FOOTPRINTS® Study Methodology and Baseline Characteristics: A 3-Year Longitudinal Study to Phenotype Patients with COPD

A Predictive Model for COPD Exacerbations Using ProAir Digihaler: A 12-Week, Open‑Label Study

Biomarkers to Predict Forced Expiratory Volume in 1 Second (FEV₁) Decline in Healthy Smokers and Early-Onset Chronic Obstructive Pulmonary Disease (COPD)

GDF-15, Pentraxin-3 and TIMP-1 Plasma Biomarkers Improve Risk Assessment for Mortality in Ambulatory Veterans with COPD

Cardiovascular Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Chronic Obstructive Pulmonary Disease (COPD): A 24-Hour Holter Monitoring Sub-Study of the ETHOS Trial

Chronic Obstructive Pulmonary Disease Plus (COPD+)^® as a Friendly App for Patients with Chronic Obstructive Pulmonary Disease

Insights from Mid-Expiratory Flow Rate (FEF_25-75%) in Ever-Smokers with Preserved Lung Function in the Subpopulations and Intermediate Markers in COPD Study (SPIROMICS) Cohort